Logo-jcvtr

J Cardiovasc Thorac Res. 2020;12(2): 90-96. doi: 10.34172/jcvtr.2020.16
PMID: 32626548        PMCID: PMC7321000

Original Article

The impact of oral nicorandil pre-treatment on ST resolution and clinical outcome of patients with acute ST-segment elevation myocardial infarction undergoing primary coronary angioplasty: A randomized placebo controlled trial

Behnaz Akbari 1, Samad Ghaffari 1 ORCID, Naser Aslanabadi 1, Bahram Sohrabi 1, Leili Pourafkari 1, Fariborz Akbarzadeh 1, Hasan Javadzadegan 1, Ahmad Separham 1 * ORCID, Malihe Sehati 1

Cited by CrossRef: 2

1- Goel H, Carey M, Elshaikh A, Krinock M, Goyal D, Nadar S. Cardioprotective and Antianginal Efficacy of Nicorandil: A Comprehensive Review. 2023;82(2):69 [Crossref]
2- Maslov L, Popov S, Naryzhnaya N, Mukhomedzyanov A, Kurbatov B, Derkachev I, Boshchenko A, Prasad N, Ma H, Zhang Y, Sufianova G, Fu F, Pei J. KATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury. Fundamemntal Clinical Pharma. 2023;37(6):1020 [Crossref]
3- Liu S, Lin L, Chen Y, Dong H, Xie S, Wang W, Huang Y, Qiu Y. Intracoronary Injection of Nicorandil Alleviates No-Reflow in Elderly Patients with Acute STEMI Undergoing Emergency PCI. International J of Pharmacology. 2024;20(6):956 [Crossref]
4- Chinese Expert Consensus on Microvascular Protection Strategy during Emergency Percutaneous Coronary Intervention Therapy in Patients with ST-elevation Myocardial Infarction. 2023; [Crossref]